ГАМКЕРГИЧЕСКИЕ МЕХАНИЗМЫ ПАТОГЕНЕЗА И ЛЕЧЕНИЯ ДЕПРЕССИВНОГО СИНДРОМА

  • И. И. Абрамец Донецкий национальный медицинский университет имени М. Горького
  • Д. В. Евдокимов Донецкий национальный медицинский университет имени М. Горького
  • Т. О. Зайка Донецкий национальный медицинский университет имени М. Горького

Аннотация

Депрессия как болезнь цивилизации весьма экстенсивно распространяется в последние три десятилетия. Имеется выраженная тенденция, что вскоре это заболевание займет одно из первых мест в общей структуре заболеваемости. Относительно невысокая терапевтическая активность в лечении депрессивного синдрома объясняется отсутствием четких представлений о его патогенезе. Моноаминергическая гипотеза патогенеза депрессии полностью исчерпала возможности лечения заболевания. Разработанные в конце 90-х — начале 2000-х годов нейротрофическая и глутаматергическая гипотезы патогенеза депрессии расширили фармакотерапевтические возможности лечения депрессии. В тоже время, механизмы патогенеза депрессии, опосредуемые нейропередачей с помощью ɣ-аминомасляной кислоты, разработаны недостаточно. В этом обзоре рассмотрено участие рецепторов ɣ-аминомасляной кислоты типов А и В нейронов лимбических структур мозга в регуляции эмоций, в патогенезе тревожных и депрессивных расстройств. Обсуждаются возможности использования лигандов указанных рецепторов в качестве психофармакологических средств для лечения депрессии.

Литература

1.Сидорова Ю.В. Нарушения психических процессов при длительном введении глюкокортикоидов в эксперименте и вероятные пути их коррекции / Ю.В. Сидорова, Д.В. Евдокимов, И.И. Абрамец // Архив клинической и экспериментальной медицины. – 2016. – №1. – С. 27–35.
2.Acosta G.B. Area-dependent changes in GABAergic function after acute and chronic cold stress / G.B. Acosta M.E. Otero Losada M.C. Rubio // Neurosci. Lett. – 1993. Vol. 154, № 2. – Р. 175–178.
3.Atack J.R. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisooxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4] triazine (MRK-016), a GABAA receptor α5 subtype-selective inverse agonist / J.R. Atack, K.A. Maubach, K.A. Wafford, D. O’Connor, A.D. Rodrigues, D. Evans et al. // J. Pharmacol. Exp. Ther. – 2009. Vol. 331, N 3. – P. 470–484.
4.Bai F. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus / F. Bai, M. Bergeron, D.L. Nelson // Neuropharmacol. – 2003. Vol. 44, N 6 – P. 1013 - 1021.
5.Behlke L.M. A pharmacogenetic ‘Restriction-of-Function’ approach reveals evidence for anxiolytic-like actions mediated by alpha5-containing GABA receptors in mice / L.M. Behlke, R.A. Foster, J. Liu, D. Benke, R.S. Benham, A.J. Nathanson et al // Neuropsychopharmacol. – 2016. Vol. 41, № 10. – P. 2492–2501.
6.Belozertseva I.V. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests / I.V. Belozertseva, T. Kos, P. Popik, W. Danysz, A.Y. Bespalov // Eur. Neuropsychopharmacol. – 2007. – Vol. 17, № 3. – P. 172−179.
7.Blackwood D.H. Schizophrenia and affective disorders – cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family / Blackwood D.H., Fordyce A., Walker M.T., St Clair M.D., Porteous D.J., Muir W.J. // Am J Hum Genet. – 2001. – № 69 (2). – С. 428 - 433.
8.Borsini F. Effect of GABAergic drugs in the behavioral ‘despair’ test in rats / F. Borsini, S. Evangelista, A. Meli. // Eur. J. Pharmacol. – 1986. – Vol. 121, № 2. – P. 265 - 268.
9.Botta P. Regulating anxiety with extrasynaptic inhibition / P. Botta, L. Demmou, Y. Kasugai, M. Markovic, C. Xu, J.P. Fadok et al. // Nat. Neurosci. – 2015. – Vol. 18, № 9. – P. 1493 – 1500.
10.Bragin A. Gamma (40-100 Hz) oscillation in the hippocampus of the behaving rat / A. Bragin, G. Jando, Z. Nadasdy, J. Hetke, K. Wise, G. Buzsaki // J. Neurosci. – 1995. – Vol. 15, № 1. – P. 47 – 60.
11.Cai X. Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression / X. Cai, A.J. Kallarackal, M.D. Kvarta, S. Goluskin, K. Gaylor, A.M. Bailey et al. // Nat. Neurosci. – 2013. – Vol. 16, № 3. – P. 464 – 472.
12.Chaki S. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity / S. Chaki, R. Yoshikawa, S. Hirota // Neuropharmacology. – 2004. – Vol. 46, № 3. – P. 457 - 467.
13.Choudary P.V. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression / P.V. Choudary, M. Molnar, S.J. Evans, H. Tomita, J.Z. Li, M.P. Vawter et al. // Proc. Nat. Acad. Sci. U.S.A. – 2005. – Vol.102, № 43. – P. 15653 – 15658.
14.Delini-Stula A. Influence of baclofen and GABA-minetic agents on spontaneous and olfactory-bulb-ablation-induced muricidal behaviour in the rat / A. Delini-Stula, A. Vassout // Arzneimittelforschung. – 1978. – Vol. 28, № 9. – P. 1508 - 1509.
15.Drexler B. Enhancing the function of alpha5-subunit-containing GABAA receptors promotes action potential firing of neocortical neurons during up-states / B.54Drexler, S. Zinser, S. Huang, M.M. Poe, U. Rudolph, J.M. Cook et al. // Eur. J. Pharmacol. – 2013. – Vol. 703, № 1-3. – P. 18 - 24.
16.Enna S.J. GABAB receptor alterationsas indicators of physiological and pharmacological function / S. J. Enna, N.G. Bowery // Biochem. Pharmacol. – 2004. – Vol. 68, № 8. – P. 1541 – 1548.
17.Farrant M. Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors / M. Farrant, Z. Nusser // Nat. Rev. Neurosci. – 2005. – Vol. 6, № 2. – P. 215 – 229.
18.Fatemi S.H. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum / S.H. Fatemi, J. M. Stary, J.A. Earle, M. Araghi-Niknam, E. Eagan // Schizophr. Res. – 2005. – Vol. 72, № 2-3. – P. 109 - 122.
19.Fischell J. Rapid antidepressant action and restoration and exicatory synaptic strength after chronic stress by negative modulators of alpha5-containing GABAA receptors / J. Fischell, A.M. Van Dyke, M. D. Kvarta, T.A. LeGates, S.M. Thompson // Neuropsychopharmacol. – 2015. – Vol. 40, № 10. – P. 2499 - 2509.
20.Froestl W. Chemistry and pharmacology of GABAB receptor ligands / W. Froestl // Adv. Pharmacol. – 2010. – Vol. 58, № 1. – P. 19 – 62.
21.Ghose S. The GABAB receptor as a target for antidepressant drug action / S. Ghose, M.K. Winter, K. E. McCarson, C.A. Tamminga, S.J. Enna // Br. J. Pharmacol. – 2011. – Vol. 162, № 1. – P. 1 - 17.
22.Gibson J.R. Functional properties of electrical synapses between inhibitory interneurons of neocortical layer 4 / J.R. Gibson, M. Beierlein, B.W. Connors // J. Neurophysiol. – 2005. Vol. 93, № 2. – P. 467 – 480.
23.Gray J.A. Increased GABAB receptor function in mouse frontal cortex after repeated administration of antidepressant drugs or electroconvulsive shock / J.A. Gray, A.R. Green // Br. J. Pharmacol. – 1987. – Vol. 92, № 2. – P. 357 – 362.
24.Guetg N. NMDA receptor-dependent GABAB receptor internalization via CaMKII phosphorylation of serine in GABAB1 / N. Guetg, S.A. Aziz, N. Holbro, R. Turecek, T. Rose, R. Seddik // Proc. Nat. Acad. Sci. USA. – 2010. – Vol. 107, № 31. – P. 13924 - 13929.
25.Guidotti A. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study / A. Guidotti, J. Auta, J.M. Davis, V. Di-Giorgi-Gerevini, Y. Dwivedi, D.R. Graysone et al. // Arch. Gen. Psychiatry. – 2000. – Vol. 57, № 11. – P. 1061 - 1069.
26.Hajуs M. Modulation of septo-hippocampal theta activity by GABAA receptors: an experimental and computational approach / M. Hajуs, W.E. Hoffmann, G. Orbon, T. Kiss, P. Erdi // Neuroscience. – 2004. – Vol. 126, № 3. – P. 599 – 610.
27.Hardingham G.E. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders /G.E. Hardingham, H. Bading .// Nat. Rev. Neurosci. – 2010. – Vol. 11, № 10. – P. 682 – 696.
28.Hood S.D. Agents in development for anxiety disorders. Current status and future potential / S.D. Hood, S.V. Argyropoulos, D.J. Nutt // CNS Drugs. – 2000. – Vol. 13, № 6. – P. 421 – 431.
29.Jacob T.C. Benzodiazepine treatment induces subtype-specific changes in GABAA receptor trafficking and decreases synaptic inhibition / T.C. Jacob, G. Michels, L. Silaveve, J. Haydon, F. Succol, S.J. Moss // Proc. Nat. Acad. Sci. USA. – 2012. – Vol. 109, № 45. – P. 18595 - 18600.
30.Jonas P. Interneuron diversity series: fast in, fast out—temporal and spatial signal processing in hippocampal interneurons / P. Jonas, J. Bischofberger, D. Fricker, R. Miles // Trends Neurosci. – 2004. –Vol. 27, № 1. – P. 30 - 40.
31.Kantamneni S. Differential regulation of GABAB receptor trafficking by different modes of N-methyl-D-aspartate (NMDA) receptor signaling / S. Kantamneni, I.M. Gonzalez-Gonzalez, J. Luo, H. Cimarosti, S.C. Jacobs, N. Jaafari et al. // J. Biol. Chem. – 2014. – Vol. 289, № 10. – P. 6681 - 6694.
32.Kavalali E.T. Synaptic mechanisms underlying rapid antidepressant action of ketamine / E.T. Kavalali, L.M. Monteggia // Am. J. Psychiatry. – 2012. – Vol. 169, № 11. – P. 1150 – 1156.
33.Kendell S.F. GABA and glutamate systems as therapeutic targets in depression and mood disorders / S.F. Kendell, J.H. Krystal, G. Sanacora // Expert. Opin. Ther. Targets. – 2005. – Vol. 9, № 1. – P. 153 - 168.
34.Krystal J.H. Glutamate and GABA systems as target for novel antidepressant and mood-stabilizing treatments / J.H. Krystal, G. Sanacora, H. Blumberg // Mol. Psychiatry. – 2002. – Vol. 7, № 3. – P. 571 - 580.
35.Kvarta M.D. Corticosterone mediates the synaptic and behavioral effects of chronic stress at rat hippocampal temporoammonic synapses / M.D. Kvarta, K.E. Bradbrook, H.M. Dantrassy, A.M. Bailey, S.M. Thompson // J. Neurophysiol. – 2015. – Vol. 114, № 3. – P. 1713 - 1724.
36.Lecca S. Rescue of GABAB and GIRK function in the lateral habenula by protein phosphatase 2A inhibition ameliorates depression-like phenotypes in mice / S. Lecca, A. Pelosi, A. Tchenio, I. Moutkine, R. Lujan, D. Herve et al. // Nat. Medicine. – 2016. – Vol. 22, № 3. – P. 254 - 261.
37.Levinson A.J. Evidence of cortical inhibitory deficits in major depressive disorder / A.J. Levinson, P.B. Fitzgerald, G. Favalli, D.M. Blumberger, M. Daigle, Z.J. Daskalakis // Biol. Psychiatry. – 2010. – Vol. 67, № 5. – P. 458 – 464.
38.Lin L.C. Somatostatin,neuronal vulnerability and behavioral emotionality // L.C. Lin, E. Sibille // Mol. Psychiatry. – 2015. – Vol. 20, № 3. – P. 377 – 387.
39.Maguire J. Neurosteroid synthesis-mediated regulation of GABA(A) receptors: relevance to the ovarian cycle and stress / J. Maguire, I. Mody // J. Neurosci. – 2007. – Vol. 27, № 9 – P. 2155 – 2162.
40.Martinez-Cue C. Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome / C. Martinez-Cue, P. Martinez, N. Rueda, R. Vidal, S. Garcia, V. Vidal et al. // J. Neurosci. – 2013. – Vol. 33, № 9. – P. 3953 - 3966.
41.Matsumoto K. GABA(A) receptor neurotransmission dysfunction in a mouse model of social isolation-induced stress: possible insights into a non-serotonergic mechanism of action of SSRIs in mood and anxiety disorders / K. Matsumoto, G. Puia, E. Dong, G. Pinna // Stress. – 2007. – Vol. 10, № 1. – P. 3 – 12.
42.McEwen B.S. Effects of adverse experiences for brain structure and function / B.S. McEwen // Biol. Psychiatry. – 2000. – Vol. 48, № 4. – P. 721 – 731.
43.Mody I. The reciprocal regulation of stress hormones and GABA(A) receptors / I. Mody, J. Maguire // Front. Cell Neurosci. – 2011. № 6, 4. doi. - 10.3389/fncel.2012.00004.
44.Mohler H. A new benzodiazepine pharmacology / H. Mohler, J.M. Fritschy, U. Rudolph // J. Parmacol. Exp. Ther. – 2002. – Vol. 300, № 1. – P. 1 - 8.
45.Mombereau C. Genetic and pharmacological evidence of a role for GABAB receptors in the modulation of anxiety and antidepressant-like behavior / C. Mombereau, K. Kaupmann, W. Froestl, G. Sansig, H. van der Putten, J.F. Cryan // Neuropsychopharmacol. – 2004. – Vol. 29, № 6. – P. 1050 – 1062.
46.Nakagawa Y. The GABAB receptor antagonist CGP36742 improves learned helplessness in rats / Y. Nakagawa, A. Sasaki, T. Takashima // Eur. J. Pharmacol. – 1999. – Vol. 381, № 1. – P. 1 – 7.
47.Nusser Z. Relative densities of synaptic and extrasynaptic GABAA receptors on cerebellar granule cells as determined by a quantitative immunogold method / Z. Nusser, J.D.B. Roberts, A. Baude, J.G.
55Richards, P. Somogyi // J. Neurosci. – 1995. – Vol. 15, № 6. – P. 2948 – 2960.
48.Olsen RW. IUPAR. LXX. Subtypes of ɣ-aminobutyric acidA receptors: classification on the basis of subunit composition, pharmacology, and function / R.W. Olsen, W. Seighart // Pharmacol. Rev. – 2008. – Vol. 60, № 3. – P. 243 - 260.
49.Packer A.M. Axo-dendritic overlap and laminar projection can explain interneuron connectivity to pyramidal cells / A.M. Packer, D.J. McConnell, E. Fino, R. Yuste // Cereb. Cortex. – 2013. – Vol. 23,- №12. – P. 790 – 2802.
50.Pantadosi S.C. Sex-dependent anti-stress effect of an a5 subunit containing GABAA receptor positive allosteric modulator / S.C. Pantadosi, B.J. French, M.M. Poe, T. Timi, B.D. Markovic, M. Pabba et al. // Front. Pharmacol. – 2016. – № 7. – P. 446.
51.Preskorn S.H. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder / S.H. Preskorn, B. Baker, S. Kolluri, F.S. Menniti, M. Krams, J.W. Landen // J. Clin. Psychopharmacol. – 2008. – Vol. 28, №6. – P. 631 - 637.
52.Rajkowska G. GABAergic neurons immunoreactivity for calcium binding proteins are reduced in the prefrontal cortex in major depression / G. Rajkowska, G. Dwyer, Z. Teleki // Neuropsychopharmacol. – 2007. – Vol. 32, №2. – P. 471 - 482.
53.Sands S.A. Effect of antidepressants on GABAB receptor function and subunit expression in the rat hippocampus / S.A. Sands, S.A. Reisman, S.J. Enna // Biochem. Pharmacol. – 2004. – Vol. 68, №8. – P. 1489 – 1495.
54.Sauer J.F. Impaired fast-spiking interneurons function in a genetic mouse model of depression / J.F. Sauer, M. Struber, M. Bartos // eLife. – 2015. – № 10. - 7554/eLife.04979
55.Slattery D.A. GABAB receptor antagonist-mediated antidepressant-like behavior is serotonin-dependent / D.A. Slattery, S. Desrayaud, J.F. Cryan // J. Pharmacol. Exp. Ther. – 2005. – Vol. 312, №2. – P. 290 – 296.
56.Stell B. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by δ subunit-containing GABAA receptors / B. Stell, S.G. Brickley, C.Y. Tang, M. Farrant, I. Mody // Proc. Nat. Acad. Sci. U S A. – 2003. – Vol. 100, № 24. – P. 14439 – 14444.
57.Thompson S. M. An excitatory synapse hypothesis of depression / S.M. Thompson, A.J. Kallarackal, M.D. Kvarta, A.M. Van Dyke, T.A. LeGates, X. Cai // Trends Neurosci. – 2015. – Vol. 38, № 5. – P. 279 – 294.
58.Tordera R.M. Enhanced anxiety, depressive-like behavior and impairment recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT 1) / R.M. Tordera, S. Totterdell, S.M. Wojcik // Eur. J. Neurosci. – 2007. – Vol. 25, № 2. – P. 281 - 290.
59.Vialou V. Prefrontal cortical circuit for depression- and anxiety-related behaviors mediated by cholecystokinin: role of ΔFosB / V. Vialou, R.C. Bagot, N.E. Cahill, D. Ferguson, A.J. Robison, D.M. Dietz et al. // J. Neurosci. – 2014. – Vol. 34, № 11. – P. 3878 - 3887.
60.Voleti B. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses / B. Voleti, A. Navarria, R.J. Liu, M. Banasr, N. Li, R. Terwilliger et al. // Biol. Psychiatry. – 2013. – Vol. 74, № 10. – P. 742–749.
61.Wohlfarth K.M. Enhanced neurosteroid potentiation of ternary GABAA receptors containing the δ subunit / K.M. Wohlfarth, M.T. Bianchi, R.L. Macdonald // J. Neurosci. – 2002. – Vol. 22, № 6. – P. 1541–1549.
62.Womelsdorf T. Modulation of neuronal interactions through neuronal synchronization / T. Womelsdorf, J.-M. Schoffelen, R. Oostenveld, W. Singer, R. Desimone, A. Engel et al. // Science. – 2007. – Vol. 316, № 5831. – P. 1609–1612.
63.Workman E.R. Rapid antidepressants stimulate decoupling of GABAB receptors from GIRK/Kir3 channels through increased protein stability of 14-3-3ƞ / E.R. Workman, P.C.G. Haddick, K. Bush, G.A. Dilly, F. Niere, B.V. Zemelman et al. // Mol. Psychiatry. – 2015. – Vol. 20, № 1. – P. 1 - 15.
64.Workman E.R. mTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABAB R signaling / E.R. Workman, F. Niere, K.F. Raab-Graham // Neuropharmacology. – 2013. – Vol. 73, № 2. – P. 192–203.
65.Zarate C.A.Jr. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression / C.A.Jr. Zarate, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, D.A. Luckenbaugh et al. // Arch. Gen. Psychiatry. – 2006. – Vol. 63, № 8. – P. 856 - 864
Опубликована
2020-07-19
Как цитировать
АБРАМЕЦ, И. И.; ЕВДОКИМОВ, Д. В.; ЗАЙКА, Т. О.. ГАМКЕРГИЧЕСКИЕ МЕХАНИЗМЫ ПАТОГЕНЕЗА И ЛЕЧЕНИЯ ДЕПРЕССИВНОГО СИНДРОМА. Архив клинической и экспериментальной медицины, [S.l.], v. 26, n. 1, p. 47-55, июль 2020. ISSN 1605-9360. Доступно на: <http://journal.dnmu.ru/index.php/akem/article/view/588>. Дата доступа: 22 сен. 2020